McKinley Carter Wealth Services Inc. Has $7.18 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

McKinley Carter Wealth Services Inc. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 1.3% in the 2nd quarter, Holdings Channel.com reports. The firm owned 13,221 shares of the medical research company’s stock after selling 177 shares during the quarter. McKinley Carter Wealth Services Inc.’s holdings in Thermo Fisher Scientific were worth $7,183,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Advanced Research Investment Solutions LLC boosted its stake in Thermo Fisher Scientific by 213.3% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 47 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 32 shares during the period. Mystic Asset Management Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Adirondack Trust Co. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $34,000. Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $38,000. Finally, Lloyd Advisory Services LLC. lifted its position in shares of Thermo Fisher Scientific by 294.1% in the 1st quarter. Lloyd Advisory Services LLC. now owns 67 shares of the medical research company’s stock worth $40,000 after acquiring an additional 50 shares during the period. Institutional investors own 86.50% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock traded down $3.63 during midday trading on Friday, reaching $516.66. 29,471 shares of the company’s stock traded hands, compared to its average volume of 1,076,331. The company has a 50-day simple moving average of $567.60 and a two-hundred day simple moving average of $558.21. Thermo Fisher Scientific Inc. has a 1-year low of $497.83 and a 1-year high of $672.34. The company has a market cap of $202.42 billion, a price-to-earnings ratio of 27.46, a PEG ratio of 1.64 and a beta of 0.85. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 0.69.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last released its earnings results on Thursday, July 28th. The medical research company reported $5.51 EPS for the quarter, beating the consensus estimate of $4.92 by $0.59. The company had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $9.95 billion. Thermo Fisher Scientific had a return on equity of 24.36% and a net margin of 17.37%. The business’s revenue for the quarter was up 18.3% on a year-over-year basis. During the same period last year, the firm earned $5.60 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 22.92 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Thursday, September 15th will be paid a $0.30 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $1.20 annualized dividend and a dividend yield of 0.23%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.39%.

Analysts Set New Price Targets

TMO has been the subject of a number of research reports. Barclays reduced their price objective on Thermo Fisher Scientific from $685.00 to $595.00 and set an “overweight” rating for the company in a research report on Monday, September 12th. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $670.00 to $678.00 and gave the stock an “overweight” rating in a research report on Friday, July 29th. Credit Suisse Group initiated coverage on Thermo Fisher Scientific in a report on Wednesday, August 24th. They issued a “neutral” rating and a $675.00 target price for the company. Finally, SVB Leerink increased their target price on Thermo Fisher Scientific from $630.00 to $650.00 and gave the stock an “outperform” rating in a report on Friday, July 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $656.56.

Insider Activity

In other news, CFO Stephen Williamson sold 15,000 shares of the firm’s stock in a transaction on Friday, August 12th. The stock was sold at an average price of $601.32, for a total value of $9,019,800.00. Following the transaction, the chief financial officer now directly owns 43,944 shares in the company, valued at approximately $26,424,406.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Stephen Williamson sold 15,000 shares of the firm’s stock in a transaction on Friday, August 12th. The stock was sold at an average price of $601.32, for a total value of $9,019,800.00. Following the transaction, the chief financial officer now directly owns 43,944 shares in the company, valued at approximately $26,424,406.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $588.36, for a total value of $5,883,600.00. Following the transaction, the chief executive officer now owns 183,373 shares in the company, valued at $107,889,338.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,397 shares of company stock valued at $33,012,754. Company insiders own 0.43% of the company’s stock.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.